Petefészekrák: vizsgálatok itt: Dél-Korea
65 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
- Where
- Gyeonggi-do, Seoul, Suwon Kyunggi-do
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07286266 · EU 2025-523361-25-00 - 1. fázisTaking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Busan, Cheongju-si, Jinju, Seoul
- Életkor
- 18 év and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00 - 1/2. fázisTaking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - 2. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Where
- Goyang-si, Seongnam-si, Seoul
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- AbbVie
See details and how to joinNCT07059845 · EU 2025-521606-18-00 - 1/2. fázisTaking peopleA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07115043 - No phaseTaking peopleProactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 1000
- Run by
- Seoul National University Hospital
See details and how to joinNCT06977594 - 1/2. fázisTaking peopleStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Where
- Seoul
- Életkor
- 18 év to 130 év
- People
- 695 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00 - 1/2. fázisTaking peoplePhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Where
- Seoul
- Életkor
- 18 év to 130 év
- People
- 622 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00 - 1/2. fázisTaking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Seoul
- Életkor
- 12 év and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - 3. fázisTaking peopleA Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 690 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07684612 · EU 2025-523366-24-00 - 1/2. fázisTaking peopleStudy of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 890 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT03564340 · EU 2024-510783-23-00 - 2. fázisTaking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Seoul
- Életkor
- 18 év to 130 év
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - 1/2. fázisTaking peopleA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Where
- Daegu, Goyang-si, Incheon, Seoul
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00 - No phaseNot yet taking people in Dél-KoreaLong Term Cohort Study of Adding Ovarian Function Suppression to Tamoxifen in Young Women
- Where
- Seoul
- Életkor
- 20 év to 45 év
- People
- 1483
- Run by
- MedicalExcellence
See details and how to joinNCT07735897 - 2. fázisTaking peopleA Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Where
- Hwasun, Pusan, Seoul, Suwon
- Életkor
- 8 év and over
- People
- 254 worldwide
- Run by
- Fore Biotherapeutics
See details and how to joinNCT05503797 · EU 2024-513578-23-00 - 3. fázisTaking peopleAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Where
- Busan, Daegu, Goyang-si, Seongnam-si, Seoul, Suwon, Yangsan
- Életkor
- 18 év and over
- People
- 1100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07218809 · EU 2025-520466-22-00 - 2. fázisTaking peopleRelacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- Where
- Gyeonggi-do, Seoul
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- Corcept Therapeutics
See details and how to joinNCT06906341 - 1. fázisTaking peopleA Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Where
- Cheongju-si, Goyang-si, Seoul
- Életkor
- 18 év and over
- People
- 1006 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04389632 · EU 2023-508469-34-00 - 1. fázisTaking peopleStudy to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Where
- Goyang-si, Seongnam, Seoul
- Életkor
- 18 év and over
- People
- 694 worldwide
- Run by
- AbbVie
See details and how to joinNCT05005403 - No phaseTaking peopleTo Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer
- Where
- Gyeonggi-do
- Életkor
- 20 év and over
- People
- 6
- Run by
- Yong Wha Moon
See details and how to joinNCT07651124 - 2. fázisTaking peopleA Study of Lorigerlimab in Participants With Advanced Solid Tumors
- Where
- Goyang-si, Seongnam-si, Seoul
- Életkor
- 18 év and over
- People
- 80 worldwide
- Run by
- MacroGenics
See details and how to joinNCT06730347 - 2. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
- Where
- Daegu, Goyang-si, Seongnam, Seongnam-si, Seoul
- Életkor
- 18 év and over
- People
- 110 worldwide
- Run by
- AbbVie
See details and how to joinNCT06682988 · EU 2024-517184-23-00 - 1. fázisTaking peopleBioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 40
- Run by
- Daewoong Pharmaceutical Co. LTD.
See details and how to joinNCT07371104 - 2. fázisTaking peopleTrastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 116 worldwide
- Run by
- Yonsei University
See details and how to joinNCT07340164 · EU 2026-527010-23-00 - 2. fázisTaking peopleNiraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
- Where
- Seoul
- Életkor
- 18 év to 99 év
- People
- 390 worldwide
- Run by
- ARCAGY/ GINECO GROUP
See details and how to joinNCT05183984 · EU 2023-504166-37-00